It's a branch of molecular biology that humans have been harnessing for centuries, but has come to carry a negative connotation for many Canadians due to concerns about genetically modified organisms: Genomics.

A recent report from the McKinsey Global Institute suggests that as much as 60% of the physical inputs to the global economy could be produced biologically, with potential savings of up to 4 TRILLION dollars per year. And as Canada works to recover from the COVID crisis, bio-manufacturing is also being billed as a massive opportunity to address issues like the supply chain vulnerabilities revealed by pandemic, as well as our reliance on foreign factories.

On this episode of RBC Disruptors, host John Stackhouse sits down with two of the country's top experts on Genomics; Doctor Rob Annan, the President and CEO of Genome Canada, and Doctor Bettina Hamelin, the President and CEO of Ontario Genomics, to learn more about the opportunities presented by the so-called "bio-revolution". He also delves into the regulatory, economic, and ethical barriers that exist, and the risks of being left behind if Canadian entrepreneurs fail to embrace this potentially transformational change.

Show notes:

The McKinsey Global Institute's report on the Bio-Revolution can be found here:

https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/the-bio-revolution-innovations-transforming-economies-societies-and-our-lives

John also references a previous episode of Disruptors featuring Canadian author Alex Lazarow, called "Beyond Silicon Valley: Why We Need a Global Playbook for Innovation," which was originally released on August 4th, 2020.